Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia

Publisher： Karger

E-ISSN： 1421-9751|135|1|3-12

ISSN： 0008-6312

Source： Cardiology, Vol.135, Iss.1, 2016-05, pp. : 3-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients

By Liem A. H.   van de Woestijne A. P.   Roeters van Lennep H. W. O.   Zwinderman A. H.   van der Steeg W. A.   Jukema J. W.  

Current Medical Research and Opinion, Vol. 24, Iss. 2, 2008-02 ,pp. : 359-364

Informa Healthcare

Access to resources Recommend Favorite

Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients

By Birjmohun R. S.   Kastelein J. J. P.   Poldermans D.   Stroes E. S. G   Hostalek U.   Assmann G.  

Current Medical Research and Opinion, Vol. 23, Iss. 7, 2007-07 ,pp. : 1707-1713

Informa Healthcare

Access to resources Recommend Favorite

Predictors of Residual Cardiovascular Risk in Patients on Statin Therapy for Primary Prevention

By  

Cardiology, Vol. 119, Iss. 4, 2011-09 ,pp. : 187-190

Karger

Access to resources Recommend Favorite

Determinants of CRP level in statin-treated patients

By Liem A. H.   van de Woestijne A. P.   Zwinderman A. H.   Visseren F. L. J.   Jukema J. W.  

Current Medical Research and Opinion, Vol. 24, Iss. 4, 2008-04 ,pp. : 1065-1068

Informa Healthcare

Access to resources Recommend Favorite

Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care

By Bestehorn Kurt   Smolka Wenefrieda   Pittrow David   Schulte Helmut   Assmann Gerd  

Current Medical Research and Opinion, Vol. 26, Iss. 12, 2010-12 ,pp. : 2833-2839

Informa Healthcare

Access to resources Recommend Favorite